Since its formal inauguration as a Health Research Institute in 2010, INCLIVA has made remarkable strides arising from its research activity. Especially noteworthy are its 8 patents and its 2 registered software programs, as well as the 2 spin-off companies which developed from research conducted at INCLIVA
INNOVATION POLICY : download
TECHNOLOGY-BASED SPIN-OFF COMPANIES:
Seqplexing is a company created in 2013 borne from the idea of generating solutions for research and clinical applications, based on introducing new techniques and advanced genomic platforms, especially next-generation sequencing (NGS). Seqplexing aims to cover the need for reliable protocols for sequencing amplicons or genes. To do this, they developed closed solutions in their laboratories that are easy to use and implement.
Seqplexing’s mission focuses on providing a service to laboratories who do not have time to develop appropriate protocols for sequencing genes or regions of interest as part of their normal work routine. Seqplexing is transforming all of the elements required to carry out these techniques into commercial kits, providing a comprehensive service from the start of sample preparation to the final analysis of the results.
Epidisease was created in 2014 as the result of a project led by INCLIVA researchers and the Centre of Networked Biomedical Research (CIBER; Centro de Investigación Biomédica en Red) in Rare Diseases in order to transfer epigenetics and biomedical sciences knowledge to the service of society.
The epigenetics field studies all the factors and mechanisms involved in controlling gene expression. The importance of this science is growing, as evidenced by some of the findings of the Human Genome Project, through which scientists realized that the molecular basis of cell function, development, aging, and many illnesses goes far beyond only DNA sequences. Recent findings from the Epigenome Road Map project are also proof of this.
Epidisease’s mission is to leverage its expertise in the field of epigenetics to provide its customers with biomedical solutions, diagnostic tools, and new therapies, as well as to stimulate translational research with the aim of improving people’s health and welfare.